SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Qantas Shares Climb as Long-Haul Pilot Deal Eases Strike Concerns 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
Apple Tests China’s CXMT Memory Chips for iPhones and MacBooks Amid AI Supply Crunch 
SK Hynix, Samsung Lead Asian Chip Stock Selloff After Sandisk, Western Digital Outlook 
Alphabet Stock Slides as Google AI Pioneer Jeff Dean Exits to Launch Discovery Loop 
DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Moderna Wins FDA Approval for mFLUSIVA mRNA Flu Vaccine for Adults 50+ 
Goldman Sachs Sees US Stock Buybacks Outpacing Equity Issuance as AI Funding Rises 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
TEMPLE CITY, Calif., Feb. 23, 2018 -- Fulgent Genetics, Inc. (NASDAQ:FLGT) (“Fulgent Genetics” or the “company”) today announced that its Chairman and Chief Executive Officer Ming Hsieh and its Chief Financial Officer Paul Kim are scheduled to participate in the 2018 BTIG Healthcare Conference on February 28, 2018 and March 1, 2018 in Snowbird, Utah.
At the conference, these representatives of the company will participate in a series of one-on-one meetings, which will not be webcast.
About Fulgent Genetics
Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in today’s market, which enables it to provide expansive options for test customization and clinically actionable results.
Investor Relations Contacts:
The Blueshirt Group
Nicole Borsje, 415-217-2633, [email protected]
